408 related articles for article (PubMed ID: 27474998)
1. Characterization of novel small-molecule NRF2 activators: Structural and biochemical validation of stereospecific KEAP1 binding.
Huerta C; Jiang X; Trevino I; Bender CF; Ferguson DA; Probst B; Swinger KK; Stoll VS; Thomas PJ; Dulubova I; Visnick M; Wigley WC
Biochim Biophys Acta; 2016 Nov; 1860(11 Pt A):2537-2552. PubMed ID: 27474998
[TBL] [Abstract][Full Text] [Related]
2. Nuclear factor (erythroid-derived 2)-like 2 (NRF2) drug discovery: Biochemical toolbox to develop NRF2 activators by reversible binding of Kelch-like ECH-associated protein 1 (KEAP1).
Bresciani A; Missineo A; Gallo M; Cerretani M; Fezzardi P; Tomei L; Cicero DO; Altamura S; Santoprete A; Ingenito R; Bianchi E; Pacifici R; Dominguez C; Munoz-Sanjuan I; Harper S; Toledo-Sherman L; Park LC
Arch Biochem Biophys; 2017 Oct; 631():31-41. PubMed ID: 28801166
[TBL] [Abstract][Full Text] [Related]
3. Monoacidic Inhibitors of the Kelch-like ECH-Associated Protein 1: Nuclear Factor Erythroid 2-Related Factor 2 (KEAP1:NRF2) Protein-Protein Interaction with High Cell Potency Identified by Fragment-Based Discovery.
Davies TG; Wixted WE; Coyle JE; Griffiths-Jones C; Hearn K; McMenamin R; Norton D; Rich SJ; Richardson C; Saxty G; Willems HM; Woolford AJ; Cottom JE; Kou JP; Yonchuk JG; Feldser HG; Sanchez Y; Foley JP; Bolognese BJ; Logan G; Podolin PL; Yan H; Callahan JF; Heightman TD; Kerns JK
J Med Chem; 2016 Apr; 59(8):3991-4006. PubMed ID: 27031670
[TBL] [Abstract][Full Text] [Related]
4. Bis-Michael Acceptors as Novel Probes to Study the Keap1/Nrf2/ARE Pathway.
Deny LJ; Traboulsi H; Cantin AM; Marsault É; Richter MV; Bélanger G
J Med Chem; 2016 Oct; 59(20):9431-9442. PubMed ID: 27682717
[TBL] [Abstract][Full Text] [Related]
5. Structural insights into the multiple binding modes of Dimethyl Fumarate (DMF) and its analogs to the Kelch domain of Keap1.
Unni S; Deshmukh P; Krishnappa G; Kommu P; Padmanabhan B
FEBS J; 2021 Mar; 288(5):1599-1613. PubMed ID: 32672401
[TBL] [Abstract][Full Text] [Related]
6. Molecular recognition between potential natural inhibitors of the Keap1-Nrf2 complex.
Bello M; Morales-González JA
Int J Biol Macromol; 2017 Dec; 105(Pt 1):981-992. PubMed ID: 28746889
[TBL] [Abstract][Full Text] [Related]
7. Recent progress in Keap1-Nrf2 protein-protein interaction inhibitors.
Mou Y; Wen S; Li YX; Gao XX; Zhang X; Jiang ZY
Eur J Med Chem; 2020 Sep; 202():112532. PubMed ID: 32668381
[TBL] [Abstract][Full Text] [Related]
8. In silico Evidence for Binding of Pentacyclic Triterpenoids to Keap1-Nrf2 Protein-Protein Binding Site.
Kamble SM; Patel HM; Goyal SN; Noolvi MN; Mahajan UB; Ojha S; Patil CR
Comb Chem High Throughput Screen; 2017; 20(3):215-234. PubMed ID: 28024463
[TBL] [Abstract][Full Text] [Related]
9. Discovery of Keap1-Nrf2 small-molecule inhibitors from phytochemicals based on molecular docking.
Li M; Huang W; Jie F; Wang M; Zhong Y; Chen Q; Lu B
Food Chem Toxicol; 2019 Nov; 133():110758. PubMed ID: 31412289
[TBL] [Abstract][Full Text] [Related]
10. Interaction Energetics and Druggability of the Protein-Protein Interaction between Kelch-like ECH-Associated Protein 1 (KEAP1) and Nuclear Factor Erythroid 2 Like 2 (Nrf2).
Zhong M; Lynch A; Muellers SN; Jehle S; Luo L; Hall DR; Iwase R; Carolan JP; Egbert M; Wakefield A; Streu K; Harvey CM; Ortet PC; Kozakov D; Vajda S; Allen KN; Whitty A
Biochemistry; 2020 Feb; 59(4):563-581. PubMed ID: 31851823
[TBL] [Abstract][Full Text] [Related]
11. Investigation of Molecular Details of Keap1-Nrf2 Inhibitors Using Molecular Dynamics and Umbrella Sampling Techniques.
Londhe AM; Gadhe CG; Lim SM; Pae AN
Molecules; 2019 Nov; 24(22):. PubMed ID: 31726716
[TBL] [Abstract][Full Text] [Related]
12. Non-covalent Small-Molecule Kelch-like ECH-Associated Protein 1-Nuclear Factor Erythroid 2-Related Factor 2 (Keap1-Nrf2) Inhibitors and Their Potential for Targeting Central Nervous System Diseases.
Pallesen JS; Tran KT; Bach A
J Med Chem; 2018 Sep; 61(18):8088-8103. PubMed ID: 29750408
[TBL] [Abstract][Full Text] [Related]
13. Discovery of a head-to-tail cyclic peptide as the Keap1-Nrf2 protein-protein interaction inhibitor with high cell potency.
Lu MC; Jiao Q; Liu T; Tan SJ; Zhou HS; You QD; Jiang ZY
Eur J Med Chem; 2018 Jan; 143():1578-1589. PubMed ID: 29117896
[TBL] [Abstract][Full Text] [Related]
14. Deconstructing Noncovalent Kelch-like ECH-Associated Protein 1 (Keap1) Inhibitors into Fragments to Reconstruct New Potent Compounds.
Pallesen JS; Narayanan D; Tran KT; Solbak SMØ; Marseglia G; Sørensen LME; Høj LJ; Munafò F; Carmona RMC; Garcia AD; Desu HL; Brambilla R; Johansen TN; Popowicz GM; Sattler M; Gajhede M; Bach A
J Med Chem; 2021 Apr; 64(8):4623-4661. PubMed ID: 33818106
[TBL] [Abstract][Full Text] [Related]
15. Replacement of a Naphthalene Scaffold in Kelch-like ECH-Associated Protein 1 (KEAP1)/Nuclear Factor (Erythroid-derived 2)-like 2 (NRF2) Inhibitors.
Richardson BG; Jain AD; Potteti HR; Lazzara PR; David BP; Tamatam CR; Choma E; Skowron K; Dye K; Siddiqui Z; Wang YT; Krunic A; Reddy SP; Moore TW
J Med Chem; 2018 Sep; 61(17):8029-8047. PubMed ID: 30122040
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and identification of novel, orally bioavailable non-covalent Nrf2 activators.
Ma B; Lucas B; Capacci A; Lin EY; Jones JH; Dechantsreiter M; Enyedy I; Marcotte D; Xiao G; Li B; Richter K
Bioorg Med Chem Lett; 2020 Feb; 30(4):126852. PubMed ID: 31898999
[TBL] [Abstract][Full Text] [Related]
17. Small molecules inhibit the interaction of Nrf2 and the Keap1 Kelch domain through a non-covalent mechanism.
Marcotte D; Zeng W; Hus JC; McKenzie A; Hession C; Jin P; Bergeron C; Lugovskoy A; Enyedy I; Cuervo H; Wang D; Atmanene C; Roecklin D; Vecchi M; Vivat V; Kraemer J; Winkler D; Hong V; Chao J; Lukashev M; Silvian L
Bioorg Med Chem; 2013 Jul; 21(14):4011-9. PubMed ID: 23647822
[TBL] [Abstract][Full Text] [Related]
18. Activation of the Nrf2/ARE pathway via S-alkylation of cysteine 151 in the chemopreventive agent-sensor Keap1 protein by falcarindiol, a conjugated diacetylene compound.
Ohnuma T; Nakayama S; Anan E; Nishiyama T; Ogura K; Hiratsuka A
Toxicol Appl Pharmacol; 2010 Apr; 244(1):27-36. PubMed ID: 20026152
[TBL] [Abstract][Full Text] [Related]
19. A systematic molecular dynamics approach to the study of peptide Keap1-Nrf2 protein-protein interaction inhibitors and its application to p62 peptides.
Lu MC; Yuan ZW; Jiang YL; Chen ZY; You QD; Jiang ZY
Mol Biosyst; 2016 Apr; 12(4):1378-87. PubMed ID: 26935067
[TBL] [Abstract][Full Text] [Related]
20. Cancer Cell Growth Is Differentially Affected by Constitutive Activation of NRF2 by KEAP1 Deletion and Pharmacological Activation of NRF2 by the Synthetic Triterpenoid, RTA 405.
Probst BL; McCauley L; Trevino I; Wigley WC; Ferguson DA
PLoS One; 2015; 10(8):e0135257. PubMed ID: 26301506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]